Business
Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) Investor Webinar with Presentation and Audience Q&A
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) Investor Webinar with Presentation and Audience Q&A\n\n\n\n TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), is pleased to invite investors and other interested parties to attend the Company’s upcoming live webinar presentation, audience Q&A and interview.\n \n\n CEO Tom Looby will discuss Conavi's unique and market-leading imaging technology for minimally invasive cardiovascular procedures.\n \n\n The webinar will be a live, interactive online event where attendees can ask the presenters questions in real time. A recording will be available for those who cannot join the live event.\n \n\n\n Event:\n \n Radius Research Pitch, Deep Dive, and Q&A with Conavi Medical Corp.\n \n\n\n Presentation Date & Time:\n \n Tuesday, June 24th @ 4 PM ET / 1 PM PT\n \n\n\n Webcast Registration Link:\n \n\n https://us02web.zoom.us/webinar/register/9717496764316/WN_FVNRHuMeRAqlOSq-U3wkCA\n \n\n\n Radius Research gives individual investors access to in-depth CEO interviews with deep-dive institutional-level discussion and Q&A. Radius Research is part of Market Radius Capital, Inc. and hosted by Martin Gagel, a former top-ranked sell-side technology and special situations analyst.\n \n\n\n About Conavi Medical Corp.:\n \n\n\n Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit\n \n conavi.com\n \n .\n \n\n\n Cautionary Statement Regarding Forward-Looking Information\n \n\n\n This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’...